Eiger BioPharmaceuticals (EIGR) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts EIGR Hot Sheet
Join SI Premium – FREE
Eiger BioPharmaceuticals (NASDAQ: EIGR) reported Q4 EPS of ($0.57), $0.04 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $4.42 million.
For earnings history and earnings-related data on Eiger BioPharmaceuticals (EIGR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BrightSpring Health Services, Inc. (BTSG) Tops Q3 EPS by 34c ; Offers Guidance
- Repligen prices $1B convertible notes due 2031 to refinance 2028 debt
- Chevron (CVX) Tops Q3 EPS by 40c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
